JP2017519807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519807A5 JP2017519807A5 JP2017501186A JP2017501186A JP2017519807A5 JP 2017519807 A5 JP2017519807 A5 JP 2017519807A5 JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017519807 A5 JP2017519807 A5 JP 2017519807A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dose
- patient
- disease
- blood concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 230000016396 cytokine production Effects 0.000 claims description 9
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 230000007823 neuropathy Effects 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 230000007658 neurological function Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 230000036765 blood level Effects 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 2
- 206010033892 Paraplegia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000032930 Spastic paraplegia Diseases 0.000 claims description 2
- 208000034799 Tauopathies Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022586P | 2014-07-09 | 2014-07-09 | |
| US62/022,586 | 2014-07-09 | ||
| PCT/US2015/039539 WO2016007616A1 (en) | 2014-07-09 | 2015-07-08 | Methods for treating neurologic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519807A JP2017519807A (ja) | 2017-07-20 |
| JP2017519807A5 true JP2017519807A5 (enExample) | 2018-08-16 |
| JP6660369B2 JP6660369B2 (ja) | 2020-03-11 |
Family
ID=55064826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501186A Active JP6660369B2 (ja) | 2014-07-09 | 2015-07-08 | 神経障害を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9579322B2 (enExample) |
| EP (1) | EP3166610B1 (enExample) |
| JP (1) | JP6660369B2 (enExample) |
| CN (3) | CN106659723A (enExample) |
| WO (1) | WO2016007616A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106659723A (zh) | 2014-07-09 | 2017-05-10 | 爱普制药有限责任公司 | 用于治疗神经病症的方法 |
| EP3368040B1 (en) * | 2015-10-26 | 2022-08-17 | Eip Pharma, LLC | Methods and compositions for recovery from stroke |
| EP3445369A4 (en) | 2016-04-21 | 2020-03-04 | Eip Pharma, LLC | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019178153A1 (en) * | 2018-03-12 | 2019-09-19 | Eip Pharma, Llc | Pharmaceutical formulations of neflamapimod |
| BR112021009653A2 (pt) * | 2018-11-20 | 2021-08-17 | Sparrow Pharmaceuticals, Inc. | método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico |
| WO2020257333A1 (en) * | 2019-06-18 | 2020-12-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
| WO2020257336A1 (en) | 2019-06-18 | 2020-12-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist |
| CA3147271A1 (en) * | 2019-07-12 | 2021-01-21 | Eip Pharma, Inc. | Compositions and methods for treating dementia with lewy bodies |
| IL302666A (en) * | 2020-11-06 | 2023-07-01 | Eip Pharma Inc | Treatment of gait dysfunction in neurodegenerative disease |
| CN113616795B (zh) * | 2021-08-31 | 2023-06-20 | 上海交通大学医学院附属瑞金医院 | Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍 |
| AU2022380947A1 (en) * | 2021-11-05 | 2024-04-11 | EIP Pharma, LLC. | Treatment of a selective population of patients having dementia with lewy bodies |
| US20240363226A1 (en) * | 2023-04-27 | 2024-10-31 | Remepy Health Ltd | Combination therapy with digital therapeutics for improved neuro-connectivity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| CN100571701C (zh) * | 2002-12-24 | 2009-12-23 | 贝卢斯健康(国际）有限公司 | 治疗β淀粉样蛋白相关疾病的治疗性制品 |
| US20050203111A1 (en) | 2004-03-12 | 2005-09-15 | Vvii Newco 2003, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| JP2007528393A (ja) | 2004-03-11 | 2007-10-11 | カイセラ バイオファーマシューティカルズ， インコーポレイテッド | 皮膚の状態および毛の状態を予防および処置するための組成物および方法 |
| KR101329112B1 (ko) * | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| EP2041078A4 (en) | 2006-06-23 | 2016-06-01 | The Feinstein Inst Medical Res | INHIBITORS OF THE ABETE SYNNUCLEINE AGGREGATION |
| CA2726588C (en) * | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| CN103596951A (zh) * | 2011-04-08 | 2014-02-19 | 阿弗拉克西斯控股股份有限公司 | 用于治疗神经系统障碍和癌症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮 |
| WO2012154814A1 (en) * | 2011-05-09 | 2012-11-15 | Eip Pharma, Llc | Compositions and methods for treating alzheimer's disease |
| CN106659723A (zh) | 2014-07-09 | 2017-05-10 | 爱普制药有限责任公司 | 用于治疗神经病症的方法 |
-
2015
- 2015-07-08 CN CN201580037336.8A patent/CN106659723A/zh active Pending
- 2015-07-08 CN CN202110783304.XA patent/CN114010641A/zh active Pending
- 2015-07-08 EP EP15819113.0A patent/EP3166610B1/en active Active
- 2015-07-08 CN CN202110348688.2A patent/CN113018300B/zh active Active
- 2015-07-08 US US14/794,469 patent/US9579322B2/en active Active
- 2015-07-08 JP JP2017501186A patent/JP6660369B2/ja active Active
- 2015-07-08 WO PCT/US2015/039539 patent/WO2016007616A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519807A5 (enExample) | ||
| Rivera-Oliver et al. | Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review | |
| Katzav et al. | Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression) | |
| JP2016199576A5 (enExample) | ||
| NO20091888L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| EA201992178A1 (ru) | Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| Khatoon et al. | The role of natural products in Alzheimer's and Parkinson's disease | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| WO2007054348A1 (de) | Neue arzneimittel | |
| Sartorius et al. | Medial Forebrain Bundle Stimulation—Speed Access to an Old or Entry into a New Depression Neurocircuit? | |
| JP7062804B2 (ja) | レビー小体病の治療および／または予防剤 | |
| Nomoto et al. | Clinical nonmotor aspect of A2A antagonist in PD treatment | |
| Faraz et al. | Effect of Hypothyroidism on Motor Nerve Conduction Studies: A Cross Sectional Study | |
| TWI723012B (zh) | 額葉功能障礙之治療劑 | |
| JP2015137243A (ja) | 脳内アミノ酸量の調整剤 | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| RU2015131803A (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| Farrell | Clinical commentary on “De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine”. | |
| Flanders et al. | PHARMACOKINETICS OF SINGLE DOSE INTRAVENOUS AND ORAL FLUNIXIN MEGLUMINE IN THE BLACK RHINOCEROS (DICEROS BICORNIS) |